A new post on Charles River’s Eureka science blog feature’s PathoQuest’s Chief Pharmaceutical Officer, Sébastien Renouf, PharmD, providing an overview of the draft ICH Q5A(R2) guidance on the testing and evaluation of the viral safety of biotechnology products derived from characterized cell lines of human or animal origin. 

Learn more about how the new ICH Q5A(R2) guidance sets the stage for the more widespread use of NGS for the test of biotechnology products derived from characterized cell lines of human or animal origin how the transition to NGS aligns with the #3Rs initiative to reduce animal testing.

CLICK HERE to read the blog post.